- Home
- PRT vs TELA Comparison
PRT vs TELA Comparison
Compare PRT & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRT | TELA |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 37.5M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PRT | TELA |
|---|---|---|
| Price | $2.95 | $0.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 52.3K | ★ 198.4K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 12.70% | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $80,275,000.00 |
| Revenue This Year | N/A | $10.23 |
| Revenue Next Year | N/A | $14.26 |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $2.61 | $0.50 |
| 52 Week High | $4.28 | $2.19 |
Technical Indicators
Market Signals| Indicator | PRT | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 35.38 | 42.52 |
| Support Level | N/A | $0.50 |
| Resistance Level | $3.57 | $1.24 |
| Average True Range (ATR) | 0.13 | 0.12 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 8.41 | 31.41 |
Price Performance
Historical ComparisonAbout PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About TELA TELA Bio Inc.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.